BioWin presents feasibility analysis report of a vaccine trial network at BioWin Days

Belgium has long been recognised as a global leader in vaccine trials, thanks to world-class expertise, strong centres of excellence and a highly integrated supply chain. Yet, this leadership is now under pressure.

At the BioWin Days, BioWin unveiled the results of a feasibility analysis on a federal vaccine trial network, carried out in collaboration with Deloitte. The study initiated at the request of the Walloon government identifies the barriers holding Belgium back, such as regulatory delays under the EU Clinical Trials Regulation, challenges in volunteer recruitment, regional imbalances in capacity, shortages of trained staff, fragmented data systems and limited dedicated infrastructure.

At the same time, the analysis highlights a unique opportunity: by connecting centres of excellence with emerging sites across regions, and investing in coordination, training, data, and community engagement, Belgium can reassert itself as one of Europe’s most attractive locations for vaccine R&D.

The goal: to set the foundations for a federal network that strengthens Belgium’s competitiveness and ensures it remains at the forefront of global vaccine research.